Floatz logo

BICALUTAMIDE

Prostate Neoplasm

Wonju Severance Christian HospitalSmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
73/ 100

Competitive context

69 Active assets in the Prostate Neoplasm cohort.

Asset / SponsorPhaseRating
Docetaxel
Merck Sharp & Dohme LLC
Phase 4BBB
PREDNISONE TABLETS
Merck Sharp & Dohme LLC
Phase 3BBB
Degarelix
Novartis Pharmaceuticals
Phase 4BBB
Abiraterone Acetate
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
LEUPROLIDE
Dana-Farber Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

BICALUTAMIDE is also rated in:

prostate adenocarcinomaActive
BB
Indicative · Phase 3
69 / 100
View asset →
triple-negative breast carcinomaActive
BB
Indicative · Phase 3
67 / 100
View asset →
prostate cancerActive
BB
Indicative · Phase 4
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →